AU Patent

AU2017242819A1 — Methods of treatment of cholestatic diseases

Assigned to Genfit SA · Expires 2018-10-11 · 8y expired

What this patent protects

The present invention relates to the use of compound 1 -[4-methylthiophenyl]-3-[3,5- dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1 -one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.

USPTO Abstract

The present invention relates to the use of compound 1 -[4-methylthiophenyl]-3-[3,5- dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1 -one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017242819A1
Jurisdiction
AU
Classification
—
Expires
2018-10-11
Drug substance claim
No
Drug product claim
No
Assignee
Genfit SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.